ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 470

Pro-Inflammatory High Density Lipoprotein Function Is Associated with Accelerated Carotid Intimal Medial Thickness Progression in Childhood-Onset SLE

Jennifer C. Cooper1, Stacy P. Ardoin2, Emily von Scheven3, Laura E. Schanberg4, Brian Skaggs5 and Maureen A. McMahon6, 1Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, 2Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, 3Pediatric Rheumatology, University of California San Francisco, San Francisco, CA, 4Duke University Medical Center, Durham, NC, 5Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 6University of California, Los Angeles, Los Angeles, CA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Arteriosclerosis, cardiovascular disease and juvenile SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Pediatric Rheumatology – Clinical Poster I: Lupus, Sjögren’s Disease, and Myositis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with childhood-onset(cSLE) are at significantly increased risk of death from cardiovascular disease when they reach early adulthood. The Atherosclerosis Prevention Pediatric Lupus Erythematous (APPLE) trial was a randomized placebo-controlled trial evaluating the effect of atorvastatin on subclinical atherosclerosis over 3 years, as measured by carotid intima-media thickness (CIMT). Results showed a trend toward reduced CIMT progression in the atorvastatin treated group and that children with SLE have CIMT progression rates greater than children with familial hypercholesterolemia. Additional subgroup analyses showed that post pubertal children with elevated C-reactive protein benefited from statin therapy. Although traditional risk factors play an important role in atherosclerosis progression, they do not fully account for the increased risk seen in SLE and additional biomarkers are needed to identify high risk individuals. Since completion of the APPLE trial, pro-inflammatory high density lipoprotein function (piHDL) function has been identified as a biomarker predictive of both the presence and progression of subclinical atherosclerosis in adult women with SLE. Although higher levels of HDL cholesterol are generally considered to be protective against atherosclerosis, HDL may become inflammatory (piHDL) in the setting of chronic inflammation and promote LDL oxidation and atherosclerosis. This is the first study to evaluate piHDL functionas a predictor of accelerated CIMT progression incSLE.

Methods: Stored baseline plasma from the APPLE trial placebo group (n=94) was tested for piHDL function using a cell-free assay based on piHDL function. Plasma samples were stored at-80°C and had not been previously thawed. Baseline and last follow-up mean mean common CIMT measurements recorded in the APPLE trial were used to calculate the rate of CIMT progression. Accelerated CIMT progression was defined as> 0.002 mm/year. Univariate logistic regression was performed to determine the association between baseline piHDL function and accelerated CIMT progression.

Results: The cohort was 87% female with a mean age of 15.7 years (standard deviation +/- 2.4). The median piHDL function was 1.04 FU, interquartile range 0.49-2.08, similar to values seen in adult women with SLE. Univariate logistic regression showed that every one point increase in piHDL function was associated with a modest yet statistically significant 1.69-fold increased odds of accelerated mean-mean common CIMT progression (95% CI1.08-2.65, p= 0.22).

Conclusion: piHDL may be a useful biomarker to aid in identifying cSLE patients at increased risk for atherosclerosis progression. Further study is underway to evaluate the predictive role of piHDL function as part of a biomarker panel in cSLE.


Disclosure: J. C. Cooper, None; S. P. Ardoin, None; E. von Scheven, None; L. E. Schanberg, SOBI, 2,Sanofi, 9,UCB, Inc., 9; B. Skaggs, None; M. A. McMahon, None.

To cite this abstract in AMA style:

Cooper JC, Ardoin SP, von Scheven E, Schanberg LE, Skaggs B, McMahon MA. Pro-Inflammatory High Density Lipoprotein Function Is Associated with Accelerated Carotid Intimal Medial Thickness Progression in Childhood-Onset SLE [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/pro-inflammatory-high-density-lipoprotein-function-is-associated-with-accelerated-carotid-intimal-medial-thickness-progression-in-childhood-onset-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pro-inflammatory-high-density-lipoprotein-function-is-associated-with-accelerated-carotid-intimal-medial-thickness-progression-in-childhood-onset-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology